Durvalumab vs Topiramate

Durvalumab vs Topiramate: Overview

This comparison examines the pharmacological differences between Durvalumab and Topiramate.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Topiramate: Multiple mechanisms: Na+ channel block, GABA enhancement, glutamate inhibition.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Topiramate — 21 hours.

Chemical Properties

Molecular Formula: Topiramate — C12H21NO8S.

Molecular Weight: Topiramate — 339.3630 g/mol.

Type: Durvalumab — Antibody; Topiramate — Small molecule.